Hamburg

DGAP-News: Hamburger Hafen und Logistik AG: HHLA shares successful 2021 business development with shareholders

Retrieved on: 
Thursday, June 16, 2022

Hamburger Hafen und Logistik AG: HHLA shares successful 2021 business development with shareholders

Key Points: 
  • Hamburger Hafen und Logistik AG: HHLA shares successful 2021 business development with shareholders
    The issuer is solely responsible for the content of this announcement.
  • The shareholders of Hamburger Hafen und Logistik AG (HHLA) are benefiting from the successful business development of 2021.
  • At the beginning of the Annual General Meeting, Chairwoman of the Executive Board Angela Titzrath looked back on a successful 2021 financial year.
  • HHLA is thus distributing a combined total of 60.1 million to the shareholders of the two subgroups for the 2021 financial year.

DGAP-News: SAF-HOLLAND SE: Scope Hamburg confirms investment grade rating

Retrieved on: 
Tuesday, April 26, 2022

SAF-HOLLAND ("SAF-HOLLAND"), one of the world's leading suppliers of trailer and truck components, today published the rating report of Scope Hamburg GmbH ("Scope Hamburg").

Key Points: 
  • SAF-HOLLAND ("SAF-HOLLAND"), one of the world's leading suppliers of trailer and truck components, today published the rating report of Scope Hamburg GmbH ("Scope Hamburg").
  • In it, Scope Hamburg sets SAF-HOLLAND SE's rating at BBB- with a stable outlook, thus confirming the investment grade rating.
  • Scope Hamburg highlights in particular the principle growth potentials from the increase in global transport volumes and the steadily increasing importance of the online business.
  • Furthermore, Scope Hamburg expects SAF-HOLLAND to also benefit from the regulatory requirements for trailers and trucks, which are intended to increase road safety and limit the effects of climate change.

ABN AMRO and receeve cement strategic partnership for collections & recovery with €4m venture investment

Retrieved on: 
Thursday, December 9, 2021

HAMBURG, Germany, Dec. 09, 2021 (GLOBE NEWSWIRE) -- receeve , the innovation leader in collections & recovery technology, is proud to announce our newest customer, ABN AMRO , the third-largest bank in the Netherlands.

Key Points: 
  • HAMBURG, Germany, Dec. 09, 2021 (GLOBE NEWSWIRE) -- receeve , the innovation leader in collections & recovery technology, is proud to announce our newest customer, ABN AMRO , the third-largest bank in the Netherlands.
  • Amsterdam-based ABN AMRO selected receeves cloud-native, all-in-one platform to future-proof experiences for its most vulnerable customers and support strategy execution across international markets.
  • Additionally, receeve and ABN AMRO Ventures are announcing a strategic partnership to boost and accelerate innovation contributing to both the banks goals and to receeves product development roadmap.
  • Organisations have to adopt agile underlying tools to wrangle the data, streamline and automate processes, optimise segmentation and repayment approaches - ABN AMRO is taking the lead in transforming collections & recovery operations.

BellaSeno Announces Publication of First-in-Human Data of its Lead Program Senella

Retrieved on: 
Tuesday, December 7, 2021

Leipzig, Germany, December 07, 2021 BellaSeno GmbH , an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the publication of first-in-human data of its lead program Senella in the European Journal of Plastic Surgery .

Key Points: 
  • Leipzig, Germany, December 07, 2021 BellaSeno GmbH , an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the publication of first-in-human data of its lead program Senella in the European Journal of Plastic Surgery .
  • The highly porous polycaprolactone implant was well tolerated by the patient and resulted in an excellent aesthetic outcome.
  • The case study describes the first-in-human trial of soft tissue engineering to camouflage a pectus excavatum defect not reconstructable by conventional techniques.
  • Senella therefore has the potential to alleviate the complications found in current breast reconstruction and augmentation approaches.

ImmunOs Therapeutics Appoints Steve Coats, PhD, as Chief Development Officer

Retrieved on: 
Monday, December 6, 2021

December 6, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Steve Coats, PhD, has been appointed as Chief Development Officer.

Key Points: 
  • December 6, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Steve Coats, PhD, has been appointed as Chief Development Officer.
  • Prior to joining ImmunOs Therapeutics, Mr. Coats served as Chief Development Officer at Auregen Biotherapeutics, managing and leading R&D laboratories to develop innovative cell therapies and building a strong development pipeline.
  • We are delighted to have Steve Coats joining ImmunOs as CDO, said Sean R. Smith, CEO of ImmunOs Therapeutics AG.
  • ImmunOs Therapeutics AG focuses on the development of a new class of biologic therapeutics for the treatment of cancer and autoimmune diseases.

Prevencio’s AI-driven HART CADhs Blood Test Significantly More Accurate than Troponin for Heart Disease Diagnosis in Diabetic Patients

Retrieved on: 
Tuesday, November 16, 2021

Prevencio, Inc. today announces the presentation of multinational patient data demonstrating its HART CADhs blood test is significantly more accurate than high sensitivity troponin in determining whether a diabetic patient has obstructive heart disease.

Key Points: 
  • Prevencio, Inc. today announces the presentation of multinational patient data demonstrating its HART CADhs blood test is significantly more accurate than high sensitivity troponin in determining whether a diabetic patient has obstructive heart disease.
  • Cardiologists from Inova Heart and Vascular Institute, Massachusetts General Hospital, and University Heart Center of Hamburg Germany collaborated to test diabetic patients for blood diagnosis of heart disease.
  • Diabetic patients are twice as likely to have heart disease compared to nondiabetic patients and require regular monitoring.
  • In addition to the HART CADhs blood test for heart disease and imminent risk of heart attack, Prevencio recently launch a second multiprotein blood test, HART CVE, for one-year risk of heart attack, stroke, or cardiac death.

ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro

Retrieved on: 
Monday, November 15, 2021

November 15, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced promising data for the Companys lead program IOS-1002 (formerly iosH2).

Key Points: 
  • November 15, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced promising data for the Companys lead program IOS-1002 (formerly iosH2).
  • "We are excited that our lead program IOS-1002 has generated such promising preclinical data both as a monotherapy and in combination with PD-1," added Sean R. Smith, Chief Executive Officer of ImmunOs Therapeutics.
  • ImmunOs Therapeutics AG focuses on the development of a new class of biologic therapeutics for the treatment of cancer and autoimmune diseases.
  • ImmunOs Therapeutics lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and activates anti-tumor responses.

Curexsys Appoints Christian Eckert as Chief Operating Officer

Retrieved on: 
Wednesday, October 20, 2021

Goettingen, Germany, October 20, 2021 - Curexsys GmbH, a leader in the emerging field of therapeutic exosomes, today announced the appointment of Christian Eckert, PhD, as Chief Operating Officer.

Key Points: 
  • Goettingen, Germany, October 20, 2021 - Curexsys GmbH, a leader in the emerging field of therapeutic exosomes, today announced the appointment of Christian Eckert, PhD, as Chief Operating Officer.
  • He joins Curexsys recently expanded management board which consists of Jrg Neermann, PhD, Chief Executive Officer, and the Companys co-founder Jens Gruber, PhD, Chief Scientific Officer.
  • "We welcome Christian Eckert to Curexsys management board," said Jrg Neermann, CEO of Curexsys.
  • Christian Eckert joins Curexsys from Bristol Myers Squibb (Juno Therapeutics GmbH), where he was responsible for GMP manufacturing, external collaborations and various steering committees.

ImmunOs Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)

Retrieved on: 
Wednesday, October 13, 2021

In addition, ImmunOs Therapeutics COO & CBO Jeffrey Abbey will attend this years virtual BIO-Europe 2021 and will be available for one-on-one meetings.

Key Points: 
  • In addition, ImmunOs Therapeutics COO & CBO Jeffrey Abbey will attend this years virtual BIO-Europe 2021 and will be available for one-on-one meetings.
  • ImmunOs Therapeutics AG focuses on the development of a new class of biologic therapeutics for the treatment of cancer and autoimmune diseases.
  • The Company has established a proprietary R&D platform for the development of HLA-based therapeutics addressing multiple targets via a single fusion protein.
  • ImmunOs Therapeutics lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and activates anti-tumor responses.

Prevencio’s Novel AI-Driven HART CADhs Blood Test Significantly More Accurate than Troponin for Obstructive Heart Disease

Retrieved on: 
Wednesday, September 1, 2021

Prevencio, Inc. today announces the presentation of multinational patient data demonstrating its Artificial Intelligence (AI)-driven HART CADhs blood test is more accurate than high sensitivity troponin in determining whether a patient has obstructive heart disease.

Key Points: 
  • Prevencio, Inc. today announces the presentation of multinational patient data demonstrating its Artificial Intelligence (AI)-driven HART CADhs blood test is more accurate than high sensitivity troponin in determining whether a patient has obstructive heart disease.
  • Cardiologists from University Heart Center of Hamburg Germany, Massachusetts General Hospital, and Inova Heart and Vascular Institute collaborated to test 924 patients for blood diagnosis of heart disease.
  • In addition to the HART CADhs blood test for heart disease and imminent risk of heart attack, Prevencio recently launched a second multiprotein blood test, HART CVE, for one-year risk of heart attack, stroke, or cardiac death.
  • Employing this novel approach, the company has developed seven blood tests that significantly improve diagnosis and risk assessment for a variety of heart and blood vessel-related complications.